Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era

Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752-w. Online ahead of print.ABSTRACTGuidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 patients with AML who underwent induction therapy before the approval of rasburicase to evaluate the incidence of TLS and the necessity of rasburicase as prophylaxis. Three patients had already developed clinical TLS (CTLS) at diagnosis of AML, and another three developed CTLS after the initiation of chemotherapy. In patients without TLS at diagnosis of AML, the risk for developing TLS was classified as high in 44 patients, intermediate in 41 and low in 57, according to the current guidelines. Allopurinol alone was administered to prevent hyperuricemia in all patients. All three patients who developed CTLS after diagnosis of AML were at high risk of TLS, and had elevated serum creatinine levels and a WBC count greater than 200,000 per microliter at diagnosis of AML. Allopurinol may be insufficient to prevent TLS in high-risk patients with renal dysfunction at diagnosis of AML, especially those with a high tumor burden and a WBC count of 200,000 or more, which indicates that prophylactic administration of rasburicase should be considered.PMID:38575822 | DOI:10.1007/s12185-024-03752-w

Source: International Journal of Hematology - April 4, 2024 Category: Hematology Authors: Yumiko Toda Masahiro Ashizawa Rui Murahashi Hirotomo Nakashima Takashi Ikeda Shin-Ichiro Kawaguchi Takashi Nagayama Kento Umino Daisuke Minakata Kaoru Morita Chihiro Yamamoto Kaoru Hatano Kazuya Sato Shin-Ichiro Fujiwara Ken Ohmine Yoshinobu Kanda Source Type: research